shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
18 October 2022Big PharmaCatherine Wycherley

Gilead inks deal for cancer-beating antibody

Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 August 2022   Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Big Pharma
4 February 2021   Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Big Pharma
7 March 2023   The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.

More on this story

Americas
23 August 2022   Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Big Pharma
4 February 2021   Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Big Pharma
7 March 2023   The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.

More on this story

Americas
23 August 2022   Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Big Pharma
4 February 2021   Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Big Pharma
7 March 2023   The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.